deBethizy J D, Udinsky J R, Scribner H E, Frederick C B
Fundam Appl Toxicol. 1987 May;8(4):549-61. doi: 10.1016/0272-0590(87)90140-0.
Following oral dosing of [2,3-14C]acrylic acid (AA; 4, 40, or 400 mg/kg) and [2,3-14C]ethyl acrylate (EA; 2, 20, or 200 mg/kg), the dosed radioactivity was rapidly excreted, with 50-75% of the dose for both compounds eliminated within 24 hr. The primary excretory metabolite for both compounds is carbon dioxide, accounting for 44-68% of the dose. HPLC analysis of the urine of AA- and EA-dosed animals indicated the presence of 3-hydroxypropionic acid. The detection of this metabolite suggests the incorporation of AA into propionic acid metabolism and may explain the rapid evolution of carbon dioxide from AA and EA. HPLC analysis of urine from EA-dosed rats revealed the presence of two metabolites derived from glutathione conjugation, N-acetyl-S-(carboxyethyl)cysteine and N-acetyl-S-(carboxyethyl)cysteine ethyl ester. The excretion of the N-acetyl cysteine derivatives of EA, expressed as a percentage of the dosed compound, decreased in a dose-dependent manner that may be attributed to the depletion of glutathione in organs primarily responsible for glutathione conjugation. No significant decrease in hepatic nonprotein sulfhydryl (NPSH) content was observed following oral dosing with EA at 2-200 mg/kg. However, the depletion of NPSH content at the dosing site, forestomach, and glandular stomach, decreased significantly between 0.02 and 0.2% EA in the dose solution (2 and 20 mg/kg). This observation would suggest that the dosing site represents a significant site of conjugation for relatively low doses of EA. Treatment with the carboxylesterase inhibitor, tri-o-cresyl phosphate (TOCP), 18 hr prior to acrylate dosing potentiated the depletion of hepatic nonprotein sulfhydryls, emphasizing the dominance of hydrolysis as a systemic detoxifying mode in this species. In contrast to EA, AA did not significantly decrease NPSH content in the liver, blood, or forestomach at oral doses of less than 8% AA in the dose solution (400 mg/kg), although a significant depletion of NPSH was observed in the glandular stomach at doses greater than 0.08% (4 mg/kg). No conjugation involving the double bond of AA could be detected in in vitro reactions with glutathione or in the in vivo metabolites, suggesting a secondary effect of AA on NPSH content in these organs. The weights of the forestomach and glandular stomach increased with AA dose, reflecting gross edema and inflammation. With EA this effect on organ weight was only demonstrated in the forestomach, and the response was increased when hydrolysis of EA was inhibited with TOCP.(ABSTRACT TRUNCATED AT 400 WORDS)
经口给予[2,3 - ¹⁴C]丙烯酸(AA;4、40或400 mg/kg)和[2,3 - ¹⁴C]丙烯酸乙酯(EA;2、20或200 mg/kg)后,给药的放射性物质迅速排出,两种化合物给药剂量的50 - 75%在24小时内被清除。两种化合物的主要排泄代谢产物都是二氧化碳,占给药剂量的44 - 68%。对给予AA和EA动物的尿液进行HPLC分析表明存在3 - 羟基丙酸。这种代谢产物的检测表明AA参与了丙酸代谢,这可能解释了AA和EA中二氧化碳的快速生成。对给予EA大鼠的尿液进行HPLC分析显示存在两种由谷胱甘肽结合产生的代谢产物,N - 乙酰 - S -(羧乙基)半胱氨酸和N - 乙酰 - S -(羧乙基)半胱氨酸乙酯。以给药化合物的百分比表示,EA的N - 乙酰半胱氨酸衍生物的排泄量呈剂量依赖性下降,这可能归因于主要负责谷胱甘肽结合的器官中谷胱甘肽的消耗。经口给予2 - 200 mg/kg的EA后,未观察到肝脏非蛋白巯基(NPSH)含量有显著下降。然而,在剂量溶液中EA浓度为0.02%至0.2%(2和20 mg/kg)时,给药部位(前胃和腺胃)的NPSH含量显著下降。这一观察结果表明,对于相对低剂量的EA,给药部位是一个重要的结合部位。在给予丙烯酸酯前18小时用羧酸酯酶抑制剂磷酸三邻甲苯酯(TOCP)进行处理,增强了肝脏非蛋白巯基的消耗,强调了水解作为该物种全身解毒方式的主导作用。与EA不同,在剂量溶液中AA口服剂量低于8%(400 mg/kg)时,肝脏、血液或前胃中的NPSH含量没有显著下降,尽管在剂量大于0.08%(4 mg/kg)时,腺胃中的NPSH有显著消耗。在与谷胱甘肽的体外反应或体内代谢产物中未检测到涉及AA双键的结合,这表明AA对这些器官中NPSH含量的影响是次要的。前胃和腺胃的重量随AA剂量增加而增加,反映出明显的水肿和炎症。对于EA,这种对器官重量的影响仅在前胃中表现出来,当用TOCP抑制EA水解时,反应增强。(摘要截短为400字)